| Year |
Citation |
Score |
| 2024 |
Levinson A, Shannon K, Huang BJ. Targeting Hyperactive Ras Signaling in Pediatric Cancer. Cold Spring Harbor Perspectives in Medicine. PMID 39009442 DOI: 10.1101/cshperspect.a041572 |
0.406 |
|
| 2023 |
Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. Jci Insight. 8. PMID 37681415 DOI: 10.1172/jci.insight.168445 |
0.462 |
|
| 2021 |
Suciu RM, Luvaga IK, Hazeen A, Weerasooriya C, Richardson SK, Firestone AJ, Shannon K, Howell AR, Cravatt BF. Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorganic & Medicinal Chemistry Letters. 128414. PMID 34666187 DOI: 10.1016/j.bmcl.2021.128414 |
0.701 |
|
| 2021 |
Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, ... ... Shannon K, et al. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nature Chemical Biology. PMID 33927411 DOI: 10.1038/s41589-021-00785-8 |
0.747 |
|
| 2020 |
Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Alzamora MDP, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, ... ... Shannon K, et al. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. Jci Insight. PMID 32990679 DOI: 10.1172/jci.insight.140495 |
0.427 |
|
| 2020 |
Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics. PMID 32847978 DOI: 10.1158/1535-7163.Mct-19-1017 |
0.389 |
|
| 2020 |
Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood. PMID 32219446 DOI: 10.1182/Blood.2019003530 |
0.784 |
|
| 2020 |
Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, ... ... Shannon K, et al. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. PMID 32066867 DOI: 10.1038/S41375-020-0748-6 |
0.331 |
|
| 2020 |
Zambetti NA, Firestone AJ, Wong JC, Long AM, Inguva A, Remsberg JR, Suciu RM, Cravatt BF, Haigis KM, Shannon K. Abstract A25: In vivo evidence validating the palmitoylation/depalmitoylation cycle as a therapeutic target in NRAS mutant hematologic cancers Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-A25 |
0.749 |
|
| 2019 |
Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. Plos One. 14: e0220026. PMID 31318944 DOI: 10.1371/Journal.Pone.0220026 |
0.35 |
|
| 2019 |
Huang BJ, Wandler AM, Meyer LK, Dail M, Daemen A, Sampath D, Li Q, Wang X, Wong JC, Nakitandwe J, Downing JR, Zhang J, Taylor BS, Shannon K. Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. Plos Genetics. 15: e1008168. PMID 31199785 DOI: 10.1371/Journal.Pgen.1008168 |
0.407 |
|
| 2019 |
Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports. 27: 631-647.e5. PMID 30970263 DOI: 10.1016/J.Celrep.2019.03.045 |
0.351 |
|
| 2018 |
Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, ... ... Shannon K, et al. Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell. PMID 30393068 DOI: 10.1016/J.Ccell.2018.10.003 |
0.422 |
|
| 2018 |
Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, ... ... Shannon K, et al. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. Jci Insight. 3. PMID 30046003 DOI: 10.1172/Jci.Insight.121086 |
0.435 |
|
| 2018 |
Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. PMID 29910151 DOI: 10.1016/J.Stem.2018.05.021 |
0.329 |
|
| 2018 |
Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. Plos One. 13: e0193849. PMID 29799846 DOI: 10.1371/Journal.Pone.0193849 |
0.441 |
|
| 2018 |
Wandler A, Shannon K. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harbor Perspectives in Medicine. 8. PMID 28778967 DOI: 10.1101/Cshperspect.A031526 |
0.496 |
|
| 2018 |
Bryant V, Wong J, Schwartz J, Lamprecht T, Ma J, Mullighan C, Loh M, Shannon K, Klco J. Abstract 2063: SAMD9/SAMD9L mutations in familial monosomy 7 Cancer Research. 78: 2063-2063. DOI: 10.1158/1538-7445.Am2018-2063 |
0.429 |
|
| 2017 |
Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, ... ... Shannon K, et al. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell. PMID 28215705 DOI: 10.1016/J.Cell.2017.01.020 |
0.734 |
|
| 2017 |
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, ... ... Shannon K, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine. PMID 28191887 DOI: 10.1038/Nm.4283 |
0.34 |
|
| 2017 |
Zambetti NA, Firestone AJ, Wong JC, Long A, Inguva A, Suciu RM, Cravatt BF, Haigis KM, Shannon KM. Genetic Validation of the Palmitoylation/Depalmitoylation Cycle As a Drug Target in NRAS Mutant Hematologic Malignancies In Vivo Blood. 130: 1221-1221. DOI: 10.1182/Blood.V130.Suppl_1.1221.1221 |
0.678 |
|
| 2016 |
Pomeroy EJ, Lee LA, Lee RD, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene. PMID 27991934 DOI: 10.1038/Onc.2016.471 |
0.505 |
|
| 2016 |
Sherborne A, Lavergne V, Yu K, Lee L, Davidson P, Mazor T, Smirnov IV, Horvai AE, Loh M, Dubois SG, Goldsby R, Neglia JP, Hammond S, Robison LL, Wustrack R, ... ... Shannon KM, et al. Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27683180 DOI: 10.1158/1078-0432.Ccr-16-0610 |
0.344 |
|
| 2016 |
Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, et al. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica. PMID 27418650 DOI: 10.3324/Haematol.2015.136002 |
0.459 |
|
| 2016 |
Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, et al. KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Reports. PMID 26854235 DOI: 10.1016/J.Celrep.2016.01.034 |
0.774 |
|
| 2016 |
White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications. 7: 10647. PMID 26854029 DOI: 10.1038/Ncomms10647 |
0.781 |
|
| 2016 |
Wandler AM, Huang B, Scacchetti A, Craig J, Yan H, Monsalve G, Li Q, Dail M, Wong JC, Nakitandwe J, Weinberg O, Hasserjian RP, Kogan SC, Sampath D, Downing JR, ... ... Shannon K, et al. Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression Blood. 128: 753-753. DOI: 10.1182/Blood.V128.22.753.753 |
0.343 |
|
| 2016 |
Puissant A, Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, ... ... Shannon K, et al. Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia Blood. 128: 523-523. DOI: 10.1182/Blood.V128.22.523.523 |
0.382 |
|
| 2016 |
Huang B, Hwang E, Wandler AM, Powell B, Bollag G, Shannon K. Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling Blood. 128: 1654-1654. DOI: 10.1182/Blood.V128.22.1654.1654 |
0.43 |
|
| 2016 |
Shannon KM. Abstract IA20: Targeting hyperactive Ras signaling in acute leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Ia20 |
0.556 |
|
| 2016 |
Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey J, Bollag G, Shannon K, Walter N, et al. Abstract LB-008: KRAS engages AGO2 to enhance cellular transformation Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-008 |
0.688 |
|
| 2015 |
Wong JC, Weinfurtner KM, Alzamora MD, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, ... Shannon K, et al. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 4. PMID 26193121 DOI: 10.7554/Elife.07839 |
0.314 |
|
| 2015 |
Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics. 47: 539-43. PMID 25822087 DOI: 10.1038/Ng.3251 |
0.523 |
|
| 2015 |
Puissant A, Fenouille N, Bassil CF, Ben-Sahra I, Alexe G, Benajiba L, Ramos A, Pikman Y, Burgess MR, Galinsky I, DeAngelo DJ, Stone RM, Shannon K, Hemann MT, Stegmaier K. Identification of CKMT1B As a New Target in EVI1-Positive AML Blood. 126: 3674-3674. DOI: 10.1182/Blood.V126.23.3674.3674 |
0.383 |
|
| 2015 |
Shannon K. Abstract IA14: Preclinical models for targeting oncogenic Ras signaling in cancer. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-Ia14 |
0.536 |
|
| 2015 |
White YN, Firestone AJ, Shannon KM. Abstract B43: Requirement for PI3 kinase interaction in K-RasG12D-driven leukemogenesis. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B43 |
0.781 |
|
| 2015 |
Eckfeldt CE, Lee RD, Pomeroy EJ, Temiz AN, Rathe SK, Ma J, Gruber TA, Diaz-Flores E, Downing JR, Shannon KM, Largaespada DA. Abstract B01: Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B01 |
0.492 |
|
| 2015 |
Shannon K. Abstract IA12: Preclinical models for targeting oncogenic Ras signaling in cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-Ia12 |
0.422 |
|
| 2015 |
Shankar S, Malik R, Kothari V, Hosono Y, Pitchiaya S, Kalyana-Sundaram S, Yocum A, Escara-Wilke J, Gundlapalli H, Chinnaswamy K, Shuler M, Poliakov A, Wang X, Krishnan V, White Y, ... ... Shannon K, et al. Abstract LB-058: Novel interactions of the RAS oncoprotein Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-058 |
0.782 |
|
| 2014 |
Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 124: 3947-55. PMID 25361812 DOI: 10.1182/Blood-2014-05-574582 |
0.764 |
|
| 2014 |
Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood. 124: 3274-83. PMID 25316678 DOI: 10.1182/Blood-2013-08-521708 |
0.426 |
|
| 2014 |
Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 513: 512-6. PMID 25043004 DOI: 10.1038/Nature13495 |
0.42 |
|
| 2014 |
Shannon K, Hermiston M. A(nother) RAF mutation in LCH Blood. 123: 3063-3065. PMID 24832939 DOI: 10.1182/Blood-2014-04-565481 |
0.401 |
|
| 2014 |
Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood. 123: 1426-7. PMID 24578498 DOI: 10.1182/Blood-2013-11-531079 |
0.439 |
|
| 2014 |
North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD. Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. Bmc Cancer. 14: 6. PMID 24386979 DOI: 10.1186/1471-2407-14-6 |
0.428 |
|
| 2014 |
Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 490-8. PMID 24178622 DOI: 10.1158/1078-0432.Ccr-13-1311 |
0.394 |
|
| 2014 |
Burgess MR, Hwang E, Wandler AM, Asthana S, Davis EM, Le Beau MM, Taylor B, Shannon K. Loss of Wild-Type Kras is Associated with Enhanced Fitness and Increased Mitogen-Activated Protein Kinase Pathway Addiction in K-RasG12D Acute Myeloid Leukemia Blood. 124: 907-907. DOI: 10.1182/Blood.V124.21.907.907 |
0.386 |
|
| 2014 |
Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Lowe SW, Shannon K, Li Q. Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia Blood. 124: 3753-3753. DOI: 10.1182/Blood.V124.21.3753.3753 |
0.781 |
|
| 2014 |
Wong JC, Weinfurtner K, Alzamora P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen S, Flach J, Reynaud D, Passegue E, Downing JR, Shannon K. Aberrant Hematopoietic Stem Cell Function in Mice Haploinsufficient for a 2 Mb Deletion of Chromosome 5A3 Syntenic to a Region of Human 7q22 Frequently Deleted in Myelodysplastic Syndromes Blood. 124: 3247-3247. DOI: 10.1182/Blood.V124.21.3247.3247 |
0.34 |
|
| 2014 |
White YN, Bagchi A, Van Ziffle J, Bollag G, Zhang C, Dickens DS, Loh ML, Shannon K, Firestone AJ. Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers Blood. 124: 2207-2207. DOI: 10.1182/Blood.V124.21.2207.2207 |
0.792 |
|
| 2014 |
Sachs Z, LaRue RS, Nguyen HT, Sachs K, Hassan NAM, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. Abstract B15: NRASG12V oncogene mediates self-renewal in a murine model of acute myelogenous leukemia Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B15 |
0.455 |
|
| 2013 |
Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, ... Shannon K, et al. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Science Signaling. 6: ra105. PMID 24300897 DOI: 10.1126/Scisignal.2004125 |
0.496 |
|
| 2013 |
Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 504: 143-7. PMID 24284627 DOI: 10.1038/Nature12830 |
0.366 |
|
| 2013 |
Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 122: 1610-20. PMID 23818547 DOI: 10.1182/Blood-2013-01-481457 |
0.33 |
|
| 2013 |
Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discovery. 3: 993-1001. PMID 23733505 DOI: 10.1158/2159-8290.Cd-13-0096 |
0.785 |
|
| 2013 |
Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood. 121: 4884-93. PMID 23637129 DOI: 10.1182/Blood-2012-05-432252 |
0.78 |
|
| 2013 |
Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, et al. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Science Signaling. 6: ra21. PMID 23532335 DOI: 10.1126/Scisignal.2003848 |
0.477 |
|
| 2013 |
Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. The Journal of Clinical Investigation. 123: 335-9. PMID 23221337 DOI: 10.1172/Jci63193 |
0.362 |
|
| 2013 |
LaRue RS, Nguyen H, Sachs K, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AG, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon K, Sachs Z, Largaespada DA. Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia Blood. 122: 819-819. DOI: 10.1182/Blood.V122.21.819.819 |
0.445 |
|
| 2013 |
Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen S, Akagi K, Lee L, Aster JC, Pear WS, Sampath D, Downing JR, Shannon K. Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones Blood. 122: 2677-2677. DOI: 10.1182/Blood.V122.21.2677.2677 |
0.402 |
|
| 2013 |
Lu J, Zavorotinskaya T, Dai Y, Niu X, Castillo J, Sim J, Yu J, Shannon K, Garcia P. Abstract 5194: Pim2 is required for maintaining Multiple Myeloma cell proliferation through modulating mTORC1 pathway. Cancer Research. 73: 5194-5194. DOI: 10.1158/1538-7445.Am2013-5194 |
0.36 |
|
| 2013 |
Dail M, Wong J, O'Connor D, Nakitandwe J, Chen S, Lawrence J, Downing JR, Sampath D, Shannon K. Abstract 4448: Notch1 inactivation contributes to PI3Ki resistance in T-ALL. Cancer Research. 73: 4448-4448. DOI: 10.1158/1538-7445.Am2013-4448 |
0.446 |
|
| 2012 |
Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 120: 3397-406. PMID 22898602 DOI: 10.1182/Blood-2012-05-378596 |
0.525 |
|
| 2012 |
Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. 119: 1032-5. PMID 22144181 DOI: 10.1182/Blood-2011-06-358960 |
0.5 |
|
| 2012 |
Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Erba HP, Green M, Poire X, Koval G, Shannon K, Atallah EL, Dy P, Smith SE, et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML). Journal of Clinical Oncology. 30: 6582-6582. DOI: 10.1200/Jco.2012.30.15_Suppl.6582 |
0.301 |
|
| 2012 |
Sachs Z, Nguyen H, Hassan NAM, Rathe SK, Sachs K, Diaz-Flores E, Bendall SC, Diers MD, Nolan GP, Shannon KM, Largaespada DA. Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature Blood. 120: 5116-5116. DOI: 10.1182/Blood.V120.21.5116.5116 |
0.44 |
|
| 2012 |
Akutagawa J, Dail M, Friedman LS, Shannon KM, Sampath D, Braun BS. The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML. Blood. 120: 2862-2862. DOI: 10.1182/Blood.V120.21.2862.2862 |
0.453 |
|
| 2012 |
Li Q, Bohin N, Wen T, Shannon KM, Morrison SJ. Oncogenic Nras Increases Hematopoietic Stem Cell Proliferation and Self-Renewal Through a Bimodal Effect Blood. 120: 119-119. DOI: 10.1182/Blood.V120.21.119.119 |
0.469 |
|
| 2012 |
Sachs Z, Rathe SK, Diaz-Flores E, Diers MD, Shannon K, Largaespada DA. Abstract 4176: Activated NRAS mediates self-renewal capacity in AML Cancer Research. 72: 4176-4176. DOI: 10.1158/1538-7445.Am2012-4176 |
0.337 |
|
| 2011 |
Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice Science Translational Medicine. 3. PMID 21451123 DOI: 10.1126/Scitranslmed.3001069 |
0.503 |
|
| 2011 |
Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, et al. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 117: 4253-61. PMID 21398220 DOI: 10.1182/Blood-2010-11-319517 |
0.386 |
|
| 2011 |
Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Research. 71: 106-15. PMID 21199799 DOI: 10.1158/0008-5472.Can-10-2732 |
0.321 |
|
| 2011 |
Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 117: 2022-32. PMID 21163920 DOI: 10.1182/Blood-2010-04-280750 |
0.487 |
|
| 2011 |
Liu H, Diaz-Flores E, Poire X, Koval G, Malnassy G, Le Beau MM, Shannon K, Odenike O, Stock W. Targeting multiple signal pathways simultaneously might provide effective therapeutic strategies in acute myeloid leukemia. Journal of Clinical Oncology. 29: 6546-6546. DOI: 10.1200/Jco.2011.29.15_Suppl.6546 |
0.407 |
|
| 2011 |
Chang TY, Krisman K, Harding-Theobald ER, Braun BS, Shannon KM. MEK Inhibition Modulates the Growth of Nf1 mutant Hematopoietic Cells and Induces Clinical Improvement in a Murine Model of Juvenile Myelomonocytic Leukemia (JMML) Blood. 118: 797-797. DOI: 10.1182/Blood.V118.21.797.797 |
0.429 |
|
| 2011 |
Sachs Z, Rathe SK, Diaz-Flores E, Diers MD, Shannon KM, Largaespada DA. Delineating Critical Effectors of Remission Induction in a Mouse Model of AML Blood. 118: 5232-5232. DOI: 10.1182/Blood.V118.21.5232.5232 |
0.368 |
|
| 2011 |
Eckfeldt CE, Diaz-Flores E, Diers MD, Rathe SK, Shannon KM, Largaespada DA. Mechanisms of Relapse Following Targeted Therapy in An NRASG12V and Mll-AF9 Driven Mouse Model of AML Blood. 118: 2620-2620. DOI: 10.1182/Blood.V118.21.2620.2620 |
0.458 |
|
| 2011 |
Shannon K, Li Q. Oncogenic Ras scales the ALPS Blood. 117: 2747-2748. DOI: 10.1182/Blood-2010-12-320721 |
0.5 |
|
| 2010 |
Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. The New England Journal of Medicine. 363: 2460-1. PMID 21067376 DOI: 10.1056/Nejme1012071 |
0.401 |
|
| 2010 |
Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. The Journal of Experimental Medicine. 207: 2581-94. PMID 21059853 DOI: 10.1084/Jem.20091071 |
0.315 |
|
| 2010 |
Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes & Development. 24: 1389-402. PMID 20595231 DOI: 10.1101/Gad.1940710 |
0.336 |
|
| 2010 |
Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proceedings of the National Academy of Sciences of the United States of America. 107: 5106-11. PMID 20194733 DOI: 10.1073/Pnas.1001064107 |
0.439 |
|
| 2010 |
Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. American Journal of Medical Genetics. Part A. 152: 4-24. PMID 20014119 DOI: 10.1002/Ajmg.A.33183 |
0.769 |
|
| 2010 |
Ward AF, Shieh A, Harding-Theobald ER, Bollag G, Shannon K. Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis Blood. 116: 4200-4200. DOI: 10.1182/Blood.V116.21.4200.4200 |
0.525 |
|
| 2010 |
Liu H, Diaz-Flores E, Poiré X, Odenike O, Koval G, Malnassy G, Ihonor P, Zhang Y, Beau MML, Shannon K, Stock W. Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia Blood. 116: 3978-3978. DOI: 10.1182/Blood.V116.21.3978.3978 |
0.41 |
|
| 2010 |
Sachs Z, Diaz-Flores E, Diers MD, Sachs K, Bendall SC, Fienberg HG, Rathe SK, Nolan GP, Shannon K, Largaespada D. Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations Blood. 116: 3160-3160. DOI: 10.1182/Blood.V116.21.3160.3160 |
0.391 |
|
| 2010 |
Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Roose J, Shokat K, Braun B, Shannon K. Abstract 3837: PI-3 kinase acts upstream of oncogenic Ras in hematopoietic cells through a cytokine-PLCγ-RasGRP pathway Cancer Research. 70: 3837-3837. DOI: 10.1158/1538-7445.Am10-3837 |
0.488 |
|
| 2010 |
Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Houseman BT, Pieper RO, Shannon K. Abstract 3427A: Focal fractionated irradiation induces specific malignancies in a dose-dependent manner in Nf1 mutant mice Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-3427A |
0.347 |
|
| 2009 |
Søvik O, Schubbert S, Houge G, Steine SJ, Norgård G, Engelsen B, Njølstad PR, Shannon K, Molven A. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. Bmj Case Reports. 2009. PMID 21686750 DOI: 10.1136/Bcr.07.2008.0550 |
0.79 |
|
| 2009 |
Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, ... ... Shannon K, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 461: 411-4. PMID 19727076 DOI: 10.1038/Nature08279 |
0.493 |
|
| 2009 |
Shannon K, Loh M. Cancer: More than kin and less than kind Nature. 460: 804-807. PMID 19675635 DOI: 10.1038/460804A |
0.342 |
|
| 2009 |
Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, ... ... Shannon KM, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 114: 1859-63. PMID 19571318 DOI: 10.1182/Blood-2009-01-198416 |
0.515 |
|
| 2009 |
Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. Plos Biology. 7: e59. PMID 19296721 DOI: 10.1371/Journal.Pbio.1000059 |
0.43 |
|
| 2009 |
Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood. 113: 1075-85. PMID 18948576 DOI: 10.1182/Blood-2008-03-144436 |
0.389 |
|
| 2009 |
Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood. 113: 1455-63. PMID 18818388 DOI: 10.1182/Blood-2008-05-159905 |
0.366 |
|
| 2009 |
Lyubynska N, Lauchle J, Shannon K, Braun BS. Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML. Blood. 114: 966-966. DOI: 10.1182/Blood.V114.22.966.966 |
0.389 |
|
| 2009 |
Niemeyer CM, Kang M, Furlan I, Shin D, Sakai DS, Heinzmann A, Archambeault S, Finklestein JZ, Mehta P, Albert MH, Kropshofer G, Corbacioglu S, Lang PJ, Erlacher M, Stary J, ... ... Shannon K, et al. Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia. Blood. 114: 310-310. DOI: 10.1182/Blood.V114.22.310.310 |
0.444 |
|
| 2009 |
Diaz-Flores E, Goldschmidt HL, Depeille P, Ng V, Roose J, Shokat K, Braun BS, Shannon K. PI3 Kinase, Phospholipase C (PLC)-γ, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells. Blood. 114: 2512-2512. DOI: 10.1182/Blood.V114.22.2512.2512 |
0.481 |
|
| 2009 |
Odenike O, Curran E, Iyengar N, Popplewell L, Kirschbaum M, Erba HP, Green M, Poiré X, Ihonor P, Diaz-Flores E, Shannon K, Atallah E, Wade JL, Perdekamp M, Nattam S, et al. Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML). Blood. 114: 2081-2081. DOI: 10.1182/Blood.V114.22.2081.2081 |
0.404 |
|
| 2009 |
Poiré X, Diaz-Flores E, Bergerson RJ, Sher D, Odenike O, Shannon K, Largaespada D, Stock W. Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression. Blood. 114: 1032-1032. DOI: 10.1182/Blood.V114.22.1032.1032 |
0.391 |
|
| 2008 |
Wong JC, Le Beau MM, Shannon K. Tumor suppressor gene inactivation in myeloid malignancies. Best Practice & Research. Clinical Haematology. 21: 601-14. PMID 19041599 DOI: 10.1016/J.Beha.2008.09.001 |
0.31 |
|
| 2008 |
Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 14: 335-43. PMID 18835035 DOI: 10.1016/J.Ccr.2008.08.014 |
0.339 |
|
| 2008 |
Braun BS, Shannon K. Targeting ras in myeloid leukemias Clinical Cancer Research. 14: 2249-2252. PMID 18413813 DOI: 10.1158/1078-0432.Ccr-07-1005 |
0.518 |
|
| 2008 |
Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics. 40: 600-8. PMID 18372904 DOI: 10.1038/Ng.115 |
0.523 |
|
| 2008 |
Shannon KM, Le Beau MM. Cancer: hay in a haystack. Nature. 451: 252-3. PMID 18202630 DOI: 10.1038/451252A |
0.404 |
|
| 2008 |
Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Human Mutation. 29: 232-9. PMID 17979197 DOI: 10.1002/Humu.20616 |
0.78 |
|
| 2008 |
Shannon K. Biology, Therapy, and Resistance of Myeloid Malignancies Initiated by Hyperactive Ras. Blood. 112. DOI: 10.1182/Blood.V112.11.Sci-9.Sci-9 |
0.568 |
|
| 2007 |
Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Molecular and Cellular Biology. 27: 7765-70. PMID 17875937 DOI: 10.1128/Mcb.00965-07 |
0.8 |
|
| 2007 |
Diaz-Flores E, Shannon K. Targeting oncogenic Ras Genes and Development. 21: 1989-1992. PMID 17699748 DOI: 10.1101/Gad.1587907 |
0.495 |
|
| 2007 |
Søvik O, Schubbert S, Houge G, Steine SJ, Norgård G, Engelsen B, Njølstad PR, Shannon K, Molven A. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. Journal of Medical Genetics. 44: e84. PMID 17601930 DOI: 10.1136/Jmg.2007.049361 |
0.789 |
|
| 2007 |
Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer Nature Reviews Cancer. 7: 295-308. PMID 17384584 DOI: 10.1038/Nrc2109 |
0.808 |
|
| 2007 |
Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD. Abnormal hematopoiesis in Gab2 mutant mice. Blood. 110: 116-24. PMID 17374739 DOI: 10.1182/Blood-2006-11-060707 |
0.364 |
|
| 2007 |
Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog Current Opinion in Genetics and Development. 17: 15-22. PMID 17208427 DOI: 10.1016/J.Gde.2006.12.004 |
0.81 |
|
| 2007 |
Shannon K, Bollag G. Sending out an SOS Nature Genetics. 39: 8-9. PMID 17192780 DOI: 10.1038/Ng0107-8 |
0.507 |
|
| 2007 |
Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 109: 3945-52. PMID 17192389 DOI: 10.1182/Blood-2006-09-047530 |
0.431 |
|
| 2007 |
Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 109: 1687-91. PMID 17090653 DOI: 10.1182/Blood-2006-05-025395 |
0.381 |
|
| 2007 |
Braun BS, Cheung LS, Chan GG, Yang WA, Archard JA, Neel BG, Shannon K. A Noncatalytic, Ras-Independent Function of SHP-2 Is Essential in Hematopoietic Progenitors. Blood. 110: 85-85. DOI: 10.1182/Blood.V110.11.85.85 |
0.524 |
|
| 2007 |
Sabnis AJ, Cheung LS, Shannon K, Braun BS. Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells. Blood. 110: 778-778. DOI: 10.1182/Blood.V110.11.778.778 |
0.456 |
|
| 2007 |
Lauchle JO, Le DT, Kim D, Akagi K, Gorman MF, Tran M, Sebolt-Leopold J, Wolff L, Parada LF, Jenkins N, Copeland N, Shannon KM. Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition. Blood. 110: 594-594. DOI: 10.1182/Blood.V110.11.594.594 |
0.431 |
|
| 2007 |
Kotecha N, Flores NJ, Irish JM, Sakaguchi D, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days. Blood. 110: 546-546. DOI: 10.1182/Blood.V110.11.546.546 |
0.336 |
|
| 2007 |
Yin B, Delwel R, Valk PJ, Loh ML, Shannon KM, Largaespada DA. Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice. Blood. 110: 2657-2657. DOI: 10.1182/Blood.V110.11.2657.2657 |
0.385 |
|
| 2007 |
Wong JC, Zhang Y, Tran MT, Lieuw KH, Wolff L, Killeen N, Shannon K. Use of Chromosome Engineering To Model a Leukemia-Associated 7q22 Deletion in the Mouse. Blood. 110: 2654-2654. DOI: 10.1182/Blood.V110.11.2654.2654 |
0.316 |
|
| 2007 |
Diaz-Flores E, VanMeter M, Lauchle JO, Braun BS, Shannon KM. Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells. Blood. 110: 2196-2196. DOI: 10.1182/Blood.V110.11.2196.2196 |
0.539 |
|
| 2007 |
Shieh AC, Shannon KM. Role of Downstream Effectors in Kras-Driven Myeloproliferative Disease. Blood. 110: 1617-1617. DOI: 10.1182/Blood.V110.11.1617.1617 |
0.54 |
|
| 2007 |
Li Q, Haigis K, McDaniel A, Huang B, Miller M, Shieh A, Kogan S, Wolff L, Jacks T, Shannon K. Expressing N-RasG12D from the Endogenous Promoter Induces Myeloproliferative Disease (MPD) and Cooperates with Retroviral Insertional Mutagenesis (RIM) To Generate Acute Myeloid Leukemia (AML). Blood. 110: 1616-1616. DOI: 10.1182/Blood.V110.11.1616.1616 |
0.407 |
|
| 2007 |
Dail M, Li Q, Lauchle J, McDaniel A, Kim D, Akagi K, Wolff L, Jenkins N, Copeland N, Shannon K. Kras
G12D
Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma. Blood. 110: 153-153. DOI: 10.1182/Blood.V110.11.153.153 |
0.436 |
|
| 2007 |
Schubbert S, Shannon K, Bollag G. Erratum: Hyperactive Ras in developmental disorders and cancer Nature Reviews Cancer. 7: 564-564. DOI: 10.1038/Nrc2175 |
0.742 |
|
| 2006 |
Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle (Georgetown, Tex.). 5: 1607-11. PMID 16921267 DOI: 10.4161/Cc.5.15.3128 |
0.815 |
|
| 2006 |
Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 108: 2041-4. PMID 16720837 DOI: 10.1182/Blood-2006-01-013490 |
0.474 |
|
| 2006 |
Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. The Journal of Clinical Investigation. 116: 847-52. PMID 16585951 DOI: 10.1172/Jci28271 |
0.318 |
|
| 2006 |
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, ... ... Shannon K, et al. Germline KRAS mutations cause Noonan syndrome. Nature Genetics. 38: 331-6. PMID 16474405 DOI: 10.1038/Ng1748 |
0.793 |
|
| 2006 |
Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood & Cancer. 46: 579-585. PMID 16261595 DOI: 10.1002/Pbc.20644 |
0.498 |
|
| 2006 |
Braun BS, Archard JA, Yang W, Chan G, Neel BG, Shannon K. Myelopoiesis Requires a Noncatalytic, Ras-Independent Function of SHP-2. Blood. 108: 635-635. DOI: 10.1182/Blood.V108.11.635.635 |
0.542 |
|
| 2006 |
Yin B, Jeske-Geurts JL, Diers MD, Shannon KM, Largaespada DA. Bcl11a Causes Leukemia/Lymphoma in Cooperation with Nf1 Inactivation. Blood. 108: 387-387. DOI: 10.1182/Blood.V108.11.387.387 |
0.362 |
|
| 2006 |
Schubbert S, Sovik O, Bollag G, Nguyen H, Rowe SL, Kratz C, Zenker MM, Niemeyer CM, Molven A, Shannon K. Biochemical and Functional Analysis of Germline KRAS Mutations That Cause Disorders of the Noonan Syndrome Spectrum. Blood. 108: 1431-1431. DOI: 10.1182/Blood.V108.11.1431.1431 |
0.803 |
|
| 2006 |
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, Burgt Ivd, Musante L, Kalscheuer V, Wehner L, Nguyen H, West B, Zhang KYJ, Sistermans E, Rauch A, ... ... Shannon K, et al. Corrigendum: Germline KRAS mutations cause Noonan syndrome Nature Genetics. 38: 598. DOI: 10.1038/Ng0506-598 |
0.751 |
|
| 2006 |
Kratz CP, Schubbert S, Zenker M, Böll S, Bollag G, Niemeyer CM, Shannon KM. Noonan syndrome and juvenile myelomonocytic leukemia: Different diseases caused by deregulation of identical pathways Leukemia Research. 30. DOI: 10.1016/S0145-2126(06)80010-X |
0.313 |
|
| 2005 |
Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 8: 337-48. PMID 16226708 DOI: 10.1016/J.Ccr.2005.08.011 |
0.368 |
|
| 2005 |
Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell. 7: 291-3. PMID 15837617 DOI: 10.1016/J.Ccr.2005.04.002 |
0.422 |
|
| 2005 |
Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K. Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. The Journal of Experimental Medicine. 201: 853-8. PMID 15781578 DOI: 10.1084/Jem.20041504 |
0.323 |
|
| 2005 |
Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood. 106: 311-7. PMID 15761018 DOI: 10.1182/Blood-2004-11-4207 |
0.797 |
|
| 2005 |
Germeshausen M, Schulze H, Kratz C, Wilkens L, Repp R, Shannon K, Welte K, Ballmaier M. An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia. Leukemia. 19: 611-7. PMID 15729385 DOI: 10.1038/Sj.Leu.2403663 |
0.358 |
|
| 2005 |
Lauchle JO, Le D, Kim D, Tran M, Peterson A, Przybranowski S, Parada L, Wolff L, Leopold J, Shannon KM. Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML). Blood. 106: 496-496. DOI: 10.1182/Blood.V106.11.496.496 |
0.441 |
|
| 2005 |
Braun BS, Archard J, Yang W, Chan G, Neel BG, Shannon KM. Oncogenic Ras Requires SHP-2 To Induce Myeloproliferative Disease (MPD). Blood. 106: 3517-3517. DOI: 10.1182/Blood.V106.11.3517.3517 |
0.562 |
|
| 2005 |
Germeshausen M, Kratz C, Ballmaier M, Shannon KM, Welte K. RAS and G-CSF Receptor Mutations Are Mutually Exclusive in Leukemogenesis in Severe Congenital Neutropenia. Blood. 106: 3073-3073. DOI: 10.1182/BLOOD.V106.11.3073.3073 |
0.39 |
|
| 2005 |
Van Meter ME, Diaz-Flores E, Archard JA, Kotecha N, Sabnis AJ, Irish JM, Nolan GP, Shannon KM, Braun BS. Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow. Blood. 106: 239-239. DOI: 10.1182/Blood.V106.11.239.239 |
0.502 |
|
| 2005 |
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Burgt Ivd, Musante L, Nguyen H, West B, Bollag G, Niemeyer CM, Shannon KM, Kratz CP. Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth. Blood. 106: 1602-1602. DOI: 10.1182/Blood.V106.11.1602.1602 |
0.821 |
|
| 2004 |
Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 6: 547-52. PMID 15607959 DOI: 10.1016/J.Ccr.2004.12.004 |
0.349 |
|
| 2004 |
Braun BS, Shannon K. The sum is greater than the FGFR1 partner Cancer Cell. 5: 203-204. PMID 15050910 DOI: 10.1016/S1535-6108(04)00060-1 |
0.328 |
|
| 2004 |
Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 103: 4243-50. PMID 14982883 DOI: 10.1182/Blood-2003-08-2650 |
0.468 |
|
| 2004 |
Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes, Chromosomes & Cancer. 39: 217-23. PMID 14732923 DOI: 10.1002/Gcc.10320 |
0.493 |
|
| 2004 |
Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America. 101: 597-602. PMID 14699048 DOI: 10.1073/Pnas.0307203101 |
0.535 |
|
| 2004 |
Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Current Opinion in Hematology. 11: 44-50. PMID 14676626 DOI: 10.1097/00062752-200401000-00007 |
0.372 |
|
| 2004 |
Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, ... Shannon KM, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 103: 2325-31. PMID 14644997 DOI: 10.1182/Blood-2003-09-3287 |
0.813 |
|
| 2004 |
Braun BS, van Ziffle J, Gavin J, Tuveson DA, Jacks T, Shannon K. Anemia and Ineffective Erythropoiesis Caused by Somatic RAS Mutation. Blood. 104: 3419-3419. DOI: 10.1182/Blood.V104.11.3419.3419 |
0.517 |
|
| 2004 |
Yin B, Walrath J, Shannon KM, Wallace MR, Largaespada DA. Genetic Dissection of Cooperating Mutations in BXH-2 Acute Myeloid Leukemia with and without Nf1 Gene Mutation. Blood. 104: 2567-2567. DOI: 10.1182/Blood.V104.11.2567.2567 |
0.386 |
|
| 2004 |
Loh M, Shannon KM. A “Ras-in-ALL” model of signaling? Blood. 104: 297-298. DOI: 10.1182/Blood-2004-05-1713 |
0.381 |
|
| 2003 |
Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials Current Opinion in Genetics and Development. 13: 84-89. PMID 12573440 DOI: 10.1016/S0959-437X(02)00016-3 |
0.313 |
|
| 2003 |
Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood. 101: 2250-2. PMID 12433685 DOI: 10.1182/Blood-2002-07-2250 |
0.457 |
|
| 2003 |
Ingram DA, Wenning MJ, Shannon K, Clapp DW. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood. 101: 1984-1986. PMID 12393498 DOI: 10.1182/Blood-2002-08-2635 |
0.426 |
|
| 2003 |
Shannon K. Bypassing the requirement for MYC in lymphoma progression Blood. 101: 2451-2451. DOI: 10.1182/Blood-2003-02-0373 |
0.389 |
|
| 2003 |
McCormick F, Shannon KM. Oncogenes and cell proliferation - Insights from inherited predispositions and mouse models: Editorial overview Current Opinion in Genetics and Development. 13: 3-5. DOI: 10.1016/S0959-437X(03)00003-0 |
0.328 |
|
| 2002 |
Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell. 2: 507-14. PMID 12498719 DOI: 10.1016/S1535-6108(02)00214-3 |
0.453 |
|
| 2002 |
Shannon KM. Resistance in the land of molecular cancer therapeutics Cancer Cell. 2: 99-102. PMID 12204529 DOI: 10.1016/S1535-6108(02)00101-0 |
0.37 |
|
| 2002 |
Dror Y, Durie P, Ginzberg H, Herman R, Banerjee A, Champagne M, Shannon K, Malkin D, Freedman MH. Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Experimental Hematology. 30: 659-69. PMID 12135662 DOI: 10.1016/S0301-472X(02)00815-9 |
0.311 |
|
| 2002 |
Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 21: 4849-54. PMID 12101424 DOI: 10.1038/Sj.Onc.1205615 |
0.329 |
|
| 2002 |
Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Current Opinion in Hematology. 9: 308-15. PMID 12042705 DOI: 10.1097/00062752-200207000-00008 |
0.466 |
|
| 2002 |
Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM. Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood. 99: 372-4. PMID 11756194 DOI: 10.1182/Blood.V99.1.372 |
0.326 |
|
| 2001 |
Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis Journal of Clinical Investigation. 108: 709-715. PMID 11544276 DOI: 10.1172/Jci12758 |
0.395 |
|
| 2001 |
Shannon KM, Le Beau MM, Largaespada DA, Killeen N. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse Seminars in Cancer Biology. 11: 191-199. PMID 11407944 DOI: 10.1006/Scbi.2001.0372 |
0.312 |
|
| 2000 |
Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM. Nf1 and Gmcsf interact in myeloid leukemogenesis. Molecular Cell. 5: 189-95. PMID 10678181 DOI: 10.1016/S1097-2765(00)80415-3 |
0.357 |
|
| 2000 |
Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo Journal of Experimental Medicine. 191: 181-187. PMID 10620616 DOI: 10.1084/Jem.191.1.181 |
0.458 |
|
| 1999 |
Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. American Journal of Medical Genetics. 89: 14-22. PMID 10469432 DOI: 10.1002/(Sici)1096-8628(19990326)89:1<14::Aid-Ajmg5>3.0.Co;2-4 |
0.474 |
|
| 1999 |
Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey PJ, Young SG. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. The Journal of Biological Chemistry. 274: 8383-90. PMID 10085069 DOI: 10.1074/Jbc.274.13.8383 |
0.466 |
|
| 1999 |
Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM. In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells Blood. 94: 2469-2476. DOI: 10.1182/Blood.V94.7.2469.419A01_2469_2476 |
0.505 |
|
| 1999 |
Mahgoub N, Taylor BR, Beau MML, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM. Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice Blood. 93: 3617-3623. DOI: 10.1182/Blood.V93.11.3617 |
0.352 |
|
| 1998 |
Shannon K. Genetic predispositions and childhood cancer Environmental Health Perspectives. 106: 801-806. PMID 9646040 DOI: 10.1289/Ehp.98106801 |
0.306 |
|
| 1998 |
Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines Journal of Experimental Medicine. 187: 1893-1902. PMID 9607929 DOI: 10.1084/Jem.187.11.1893 |
0.373 |
|
| 1998 |
Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, Masterson M, Shannon KM, Felix CA. RAS mutations in pediatric leukemias with MLL gene rearrangements Genes, Chromosomes and Cancer. 21: 270-275. PMID 9523205 DOI: 10.1002/(Sici)1098-2264(199803)21:3<270::Aid-Gcc14>3.0.Co;2-T |
0.497 |
|
| 1998 |
Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 92: 267-272. DOI: 10.1182/Blood.V92.1.267.413A31_267_272 |
0.44 |
|
| 1997 |
Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. The New England Journal of Medicine. 336: 1713-20. PMID 9180088 DOI: 10.1056/Nejm199706123362404 |
0.398 |
|
| 1997 |
Bollag G, Adler F, elMasry N, McCabe PC, Conner E, Thompson P, McCormick F, Shannon K. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. The Journal of Biological Chemistry. 271: 32491-4. PMID 8955068 DOI: 10.1074/Jbc.271.51.32491 |
0.543 |
|
| 1997 |
Shannon KM. #402 Pertubations of the Ras signaling pathway in myeloid leukemogenesis Journal of Pediatric Hematology/Oncology. 19: 355. DOI: 10.1097/00043426-199707000-00020 |
0.326 |
|
| 1996 |
Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics. 12: 144-8. PMID 8563751 DOI: 10.1038/Ng0296-144 |
0.481 |
|
| 1996 |
Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM. Patterns of Hematopoietic Lineage Involvement in Children With Neurofibromatosis Type 1 and Malignant Myeloid Disorders Blood. 88: 4314-4320. DOI: 10.1182/Blood.V88.11.4314.Bloodjournal88114314 |
0.317 |
|
| 1996 |
Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Erratum: Corrigendum: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells Nature Genetics. 12: 458-458. DOI: 10.1038/Ng0496-458C |
0.445 |
|
| 1995 |
Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis Current Opinion in Hematology. 2: 305-308. PMID 9372012 DOI: 10.1097/00062752-199502040-00011 |
0.432 |
|
| 1995 |
Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, Olson K, Paderanga D, Shannon K. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia Blood. 86: 4579-4586. DOI: 10.1182/Blood.V86.12.4579.Bloodjournal86124579 |
0.456 |
|
| 1994 |
Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. The New England Journal of Medicine. 330: 597-601. PMID 8302341 DOI: 10.1056/Nejm199403033300903 |
0.347 |
|
| 1994 |
Kalra R, Paderanga D, Olson K, Shannon K. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras Blood. 84: 3435-3439. DOI: 10.1182/Blood.V84.10.3435.Bloodjournal84103435 |
0.517 |
|
| 1992 |
Shannon K, Watterson J, Johnson P, O'Connell P, Lange B, Shah N, Steinherz P, Kan Y, Priest J. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood. 79: 1311-1318. DOI: 10.1182/Blood.V79.5.1311.Bloodjournal7951311 |
0.32 |
|
| 1991 |
Neubauer A, Shannon K, Liu E. Mutations of the ras proto-oncogenes in childhood monosomy 7 Blood. 77: 594-598. DOI: 10.1182/BLOOD.V77.3.594.BLOODJOURNAL773594 |
0.432 |
|
| 1991 |
Neubauer A, Shannon K, Liu E. Mutations of the ras proto-oncogenes in childhood monosomy 7 Blood. 77: 594-598. DOI: 10.1182/blood.v77.3.594.594 |
0.432 |
|
| 1985 |
Shannon K, Cowan MJ, Ball E, Abrams D, Volberding P, Ammann AJ. Impaired mononuclear-cell proliferation in patients with the acquired immune deficiency syndrome results from abnormalities of both T lymphocytes and adherent mononuclear cells. Journal of Clinical Immunology. 5: 239-245. PMID 3876352 DOI: 10.1007/Bf00929458 |
0.309 |
|
| Show low-probability matches. |